JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Aperta

2.57 23.56

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.03

Massimo

2.69

Metriche Chiave

By Trading Economics

Entrata

-6.4M

-53M

Vendite

-9.6M

47M

Margine di Profitto

-112.813

Dipendenti

580

EBITDA

-28M

-49M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+89.55% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

55M

829M

Apertura precedente

-20.99

Chiusura precedente

2.57

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2025, 17:49 UTC

I principali Market Mover

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

I principali Market Mover

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Utili

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Discorsi di Mercato

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Discorsi di Mercato

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Discorsi di Mercato

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Discorsi di Mercato

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Discorsi di Mercato

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Discorsi di Mercato

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Discorsi di Mercato

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Discorsi di Mercato

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

89.55% in crescita

Previsioni per 12 mesi

Media 4.17 USD  89.55%

Alto 7 USD

Basso 2 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.02 / 2.115Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.